What Happened?
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ: TNDM) jumped 5% in the morning session after the company announced the publication of a study showing its automated insulin delivery system was beneficial for adults with type 2 diabetes, while a broader market rally fueled by a Federal Reserve interest rate cut also provided a tailwind.
The study, published in the American Diabetes Association's Diabetes Care journal, found that the Control-IQ+ system helped adults with insulin-treated type 2 diabetes, regardless of their C-peptide levels. This positive news arrived in a favorable market environment. The U.S. Federal Reserve initiated its first interest rate cut of 2025, which buoyed investor sentiment and sent stocks higher for a third straight session. Capital-intensive sectors like biotechnology and healthcare particularly benefited from the signal of improved funding conditions. The specific clinical update, combined with the broader economic tailwind, helped lift the shares.
Is now the time to buy Tandem Diabetes? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Tandem Diabetes’s shares are extremely volatile and have had 34 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 29 days ago when the stock dropped 5.5% on the news that the major indices continued to pull back, with technology stocks accounting for most of the market's largest decliners.
A key reason for this trend is that much of the recent market gains were concentrated in the "AI trade," which includes these large technology and semiconductor companies. So this could also mean that some investors are locking in some gains ahead of more definitive feedback from the Fed.
Despite the downturn, some analysts viewed this as an opportunity to own some of the "Core AI winners." Dan Ives of Wedbush Securities commented, "In our view, the tech bull cycle will be well intact for at least another 2-3 years, given the trillions being spent on AI infrastructure/software/chips/power/apps looking ahead. This remains our tech playbook and investor roadmap."
Additionally, mixed earnings reports from retailers, such as Target, added to the market's weakness.
Tandem Diabetes is down 63.9% since the beginning of the year, and at $12.93 per share, it is trading 71.6% below its 52-week high of $45.44 from September 2024. Investors who bought $1,000 worth of Tandem Diabetes’s shares 5 years ago would now be looking at an investment worth $121.48.
Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.
